A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

Inclusion Criteria:

• Pathologically or cytologically confirmed, advanced or refractory tumors (there areno restriction on the total number of lines of prior therapies, but participantshould have received at least 1 line of anti-cancer therapy [as per local standardof care]): Squamous and non-squamous non-small-cell lung cancer (NSCLC), esophagealcancer, urothelial cancer and cholangiocarcinoma

• Participants must meet the following molecular eligibility criteria (diagnosed at acentral or local laboratory using either a tumor tissue based assay, which mustindicate: at least one of following): a) fibroblast growth factor receptor (FGFR)gene translocations b) FGFR gene mutations c) Participants with evidence of FGFRpathway activation or other potential target/pathway inhibited by erdafitinib mayalso be considered and allowed for enrollment if supported by emerging biomarkerdata.

• The presence of measurable disease according to the RECIST, Version 1.1 Criteria,and documented disease progression as defined by RECIST (Version 1.1) at baseline

• Eastern Cooperative Oncology Group (ECOG) performance status score 0 or 1

• Female participants (of child bearing potential and sexually active) and maleparticipants (with a partner of child bearing potential) must use medicallyacceptable methods of birth control. Male participants must use highly effectivebirth control measurements when sexually active and must not donate sperm

• Adequate bone marrow, liver, and renal function within the 14 days prior to Day 1 ofCycle 1 up until pre-dose of Cycle 1

Exclusion Criteria:

• Chemotherapy, targeted therapies, immunotherapy, or treatment with aninvestigational anticancer agent within 2 weeks or at least 5 half-lives of the drugwhichever is longer up to a maximum of 4 weeks before the first administration ofstudy drug. Localized palliative radiation therapy (but should not include radiationto target lesions) and ongoing luteinizing hormone-releasing hormone (LHRH)agonists, bisphosphonates and denosumab, are permitted

• Participants with persistent phosphate greater than (>) upper limit of normal (ULN)during Screening (within 14 days prior to Day 1 of Cycle 1 up until pre-dose ofCycle 1) and despite medical management of phosphate levels

• Participants taking medications known to have a significant risk of causing QTcprolongation and Torsades de Pointes. Participants who have discontinued any ofthese medications must have a wash-out period of at least 5 days or at least 5half-lives of the drug (whichever is longer) prior to the first dose of study drug

• Left ventricular ejection fraction (LVEF) less than (<) 50% as assessed byechocardiography (or multi-gated acquisition [MUGA]) performed at Screening

• Uncontrolled inter-current illness including, but not limited to, poorly controlledhypertension or diabetes, ongoing active infection requiring antibiotics,psychiatric illness, or at risk of gastrointestinal perforation as perinvestigators' assessment

• Received prior selective FGFR inhibitor treatment or RET inhibitor treatment,respectively according to the biomarker prescreening result, or if the participanthas known allergies, hypersensitivity, or intolerance to Erdafitinib or itsexcipients

• Any corneal or retinal abnormality likely to increase risk of eye toxicity